Superworth

Akebia Therapeutics EPS AKBA

Diluted earnings per share by quarter and over the last twelve months, from 2013.

Last 12 months, to Jun 30, 2026
−$0.11
Latest quarter, Q2 FY26
−$0.03
Fiscal year 2025
−$0.02

Akebia Therapeutics' earnings per share was −$0.11 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.03.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.02n/a
FY2024−$0.33n/a
FY2023−$0.29n/a
FY2022−$0.52n/a
FY2021−$1.70n/a
FY2020−$2.77n/a
FY2019−$2.36n/a
FY2018−$2.41n/a
FY2017−$1.84n/a
FY2016−$3.60n/a
FY2015−$2.27n/a
FY2014−$44.75n/a
FY2013−$132.08n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.03n/a−$0.11
Q1 FY26−$0.03−200%−$0.08
Q4 FY25−$0.05n/a−$0.02
Q3 FY25$0.00n/a−$0.07
Q2 FY25$0.00n/a−$0.17
Q1 FY25$0.03n/a−$0.21
Q4 FY24−$0.10n/a−$0.33
Q3 FY24−$0.10n/a−$0.23
Q2 FY24−$0.04n/a−$0.21
Q1 FY24−$0.09n/a−$0.23
Q4 FY23$0.00n/a−$0.29
Q3 FY23−$0.08n/a−$0.32

Against its peers

Companies in Drug Manufacturers - General nearest Akebia Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
AKBAAkebia Therapeutics−$0.11
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ARVNArvinas$0.16
ATNMActinium Pharmaceuticals$0.36
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Akebia Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.